Stockscreener 앱 받기
7.27
2.25%
0.16
시간 외 거래:
7.28
0.01
+0.14%
전일 마감가:
$7.11
열려 있는:
$7.11
하루 거래량:
126.33K
Relative Volume:
0.91
시가총액:
$313.50M
수익:
$239.40M
순이익/손실:
$104.44M
주가수익비율:
2.4561
EPS:
2.96
순현금흐름:
$-18.50M
1주 성능:
+2.97%
1개월 성능:
-10.69%
6개월 성능:
-58.36%
1년 성능:
-48.07%
1일 변동 폭
$7.085
$7.41
1주일 범위
$6.585
$7.41
52주 변동 폭
$6.585
$21.79
Entrada Therapeutics Inc Stock (TRDA) Company Profile
명칭
Entrada Therapeutics Inc
전화
857-305-1825
주소
ONE DESIGN CENTER PLACE, BOSTON
TRDA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
7.27 | 313.50M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-06 | 개시 | ROTH MKM | Buy |
| 2024-01-05 | 개시 | Oppenheimer | Outperform |
| 2023-04-03 | 개시 | H.C. Wainwright | Buy |
Entrada Therapeutics Inc 주식(TRDA)의 최신 뉴스
(TRDA) Long Term Investment Analysis - news.stocktradersdaily.com
Harbor Capital Advisors Inc. Makes New Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Wall Street Zen Downgrades Entrada Therapeutics (NASDAQ:TRDA) to Sell - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 21,594 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Millennium Management LLC Sells 98,416 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics Holds Virtual Annual Stockholders Meeting - TipRanks
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Holdings Raised by Bank of America Corp DE - Defense World
Transcript : Entrada Therapeutics, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 08 - MarketScreener
Mackenzie Financial Corp Makes New Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
How the (TRDA) price action is used to our Advantage - news.stocktradersdaily.com
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Position Trimmed by Nuveen Asset Management LLC - Defense World
Entrada Therapeutics expands board with new director By Investing.com - Investing.com South Africa
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors - GlobeNewswire
Entrada Therapeutics expands board with new director - Investing.com
Entrada Therapeutics (TRDA) Welcomes New Board Member | TRDA Stock News - GuruFocus
Entrada Therapeutics Appoints New Board Member - TipRanks
3,324 Shares in Entrada Therapeutics, Inc. (NASDAQ:TRDA) Bought by BNP Paribas Financial Markets - Defense World
Ameriprise Financial Inc. Buys 2,517 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Buy Rating for Entrada Therapeutics: Strategic Positioning and Regulatory Advances in Exon-Skipping Therapeutics - TipRanks
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - MarketScreener
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Entrada Therapeutics Awards Nearly 24,000 RSUs in Latest Employee Compensation Plan - Stock Titan
Deutsche Bank AG Grows Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics to start DMD trial in Q3 2025 By Investing.com - Investing.com South Africa
Entrada Therapeutics (TRDA) Gains EU Approval for Advanced Clinical Study | TRDA Stock News - GuruFocus
Entrada Therapeutics to start DMD trial in Q3 2025 - Investing.com
Entrada Therapeutics Receives EU Authorization to Proceed with ELEVATE-45-201 Clinical Study for Duchenne Muscular Dystrophy, Set to Begin in Q3 2025 - Nasdaq
Breakthrough DMD Treatment Gets EU Green Light: Entrada's Novel Exon 45 Therapy Heads to Clinical Trials - Stock Titan
HC Wainwright Brokers Boost Earnings Estimates for TRDA - Defense World
Layoff Tracker: Boundless Laying Off 33% of Staff - BioSpace
Q2 Earnings Forecast for TRDA Issued By HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for Entrada Therapeutics (NASDAQ:TRDA) - Defense World
Northern Trust Corp Has $5.50 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics (TRDA) Receives 'Buy' Rating Reiteration by HC Wainwright | TRDA Stock News - GuruFocus
Tower Research Capital LLC TRC Cuts Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
(TRDA) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Roth Capital Issues Negative Outlook for TRDA Earnings - Defense World
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Entrada Therapeutics price target lowered to $21 from $23 at Roth Capital - TipRanks
Entrada Therapeutics (TRDA) Sees Price Target Adjustment Amid Cl - GuruFocus
Roth Capital Adjusts Price Target for Entrada Therapeutics (TRDA - GuruFocus
Roth Capital Adjusts Price Target for Entrada Therapeutics (TRDA) | TRDA Stock News - GuruFocus
Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results - Yahoo Finance
Entrada Therapeutics: Strategic Advancements in DMD Pipeline Drive Buy Rating - TipRanks
Entrada Therapeutics reports Q1 EPS (42c), consensus (77c) - TipRanks
Entrada Therapeutics earnings beat by $0.31, revenue fell short of estimates - Investing.com
Entrada Therapeutics (TRDA) Reports Strong Q1 Revenue and Advances Duchenne Programs | TRDA Stock News - GuruFocus
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Entrada Therapeutics Reports First Quarter 2025 Financial Results - The Manila Times
First Trust Advisors LP Sells 7,800 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
MetLife Investment Management LLC Acquires 1,731 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics Inc (TRDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.45%
0.86%
자본화:
|
볼륨(24시간):